SPRO Overview

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Wall Street analysts forecast SPRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Spero Therapeutics Inc revenue for the last quarter amounts to 41.30M USD, increased 174.51

Spero Therapeutics Inc. EPS for the last quarter amounts to 0.46 USD, decreased -221.05

Spero Therapeutics Inc (SPRO) has 25 emplpoyees as of April 15 2026.

Today SPRO has the market capitalization of 160.94M USD.